Public Company Software

Certara

Radnor, Pennsylvania, United States

Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Clients include biopharmaceutical companies, academic institutions, and regulatory agencies across multiple countries.

Focus Areas
Biosimulation, Model-informed drug development, Quantitative systems pharmacology (QSP)
Website
certara.com

Tracked deals

4

4 tracked deals across 2021-2024.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Buyout

4 buyout

Certara Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for Certara. 1 2021 2 2023 1 2024

Supporting Data

Recent Transactions

  • Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities
    July 9, 2024
    Buyer
    Certara, Inc.
    Target
    Chemaxon
    Industry
    Software
    Location
    Hungary
    Type
    Buyout

    Certara, Inc. has signed a definitive agreement to acquire Chemaxon, a leading cheminformatics software provider, with the transaction expected to close in the second half of 2024, subject to regulatory approvals. The acquisition adds Chemaxon’s discovery-focused cheminformatics tools to Certara’s biosimulation portfolio, enabling a more comprehensive data and predictive-analytics platform spanning discovery through development.

  • Certara Acquires Applied BioMath
    December 14, 2023
    Buyer
    Certara, Inc.
    Target
    Applied BioMath
    Industry
    Biotechnology
    Location
    Massachusetts, United States
    Type
    Buyout

    Certara, Inc. has acquired Applied BioMath to expand its biosimulation capabilities and establish the life sciences industry's largest quantitative systems pharmacology (QSP) center of excellence. The acquisition combines Certara's biosimulation and AI portfolios with Applied BioMath's proprietary QSP platform and modeling expertise to industrialize QSP and accelerate drug development.

  • Certara Acquires Vyasa Analytics
    January 4, 2023
    Buyer
    Certara, Inc.
    Target
    Vyasa Analytics, LLC
    Industry
    AI & Machine Learning
    Location
    Massachusetts, United States
    Type
    Buyout

    Certara, Inc. (Nasdaq: CERT) has acquired Vyasa Analytics, LLC to integrate Vyasa’s deep-learning platform LAYAR and AI capabilities into Certara’s biosimulation software suite. The acquisition expands Certara’s data fabric and AI-driven prediction capabilities to accelerate drug discovery and development.

  • Certara Acquires Pinnacle 21
    October 4, 2021
    Buyer
    Certara, Inc.
    Target
    Pinnacle 21
    Seller
    Equity holders of Pinnacle 21
    Industry
    Software
    Location
    Pennsylvania, United States
    Type
    Buyout

    Certara, Inc. completed the acquisition of Pinnacle 21, a provider of SaaS solutions for clinical data standardization, validation and regulatory-submission readiness. Equity holders of Pinnacle 21 received approximately $250 million in cash and 2,239,717 restricted shares of Certara common stock; Certara said the deal expands its data-sciences and software capabilities and is expected to be accretive to revenue and adjusted EBITDA.

Related Acquisition Pages

Software Buyers & Acquisitions 2 tracked deals by Certara. AI & Machine Learning Buyers & Acquisitions 1 tracked deal by Certara. Biotechnology Buyers & Acquisitions 1 tracked deal by Certara. Acquisitions in Massachusetts 2 tracked deals by Certara. Acquisitions in Pennsylvania 1 tracked deal by Certara.

Related articles

Selling a company? Get in front of buyers like Certara

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →